Cryoport, Inc.
NASDAQ•CYRX
執行長: Mr. Jerrell W. Shelton
板塊: Industrials
行業: Integrated Freight & Logistics
上市日期: 2005-08-22
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
聯絡資訊
市值
$391.54M
本益比 (TTM)
5.0
35.8
股息率
--
52周最高
$11.45
52周最低
$4.63
52周範圍
排名63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
疲弱 • 1.8 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025
財務儀表板
Q4 2025 數據
營業收入
$45.45M+0.00%
近4季度走勢
每股收益
-$0.21+0.00%
近4季度走勢
自由現金流
-$15.73M+0.00%
近4季度走勢
2025 Annual 財報亮點
核心亮點
Total Revenue Growth Total revenue reached $176.2M, marking a 12.4% increase. Life Sciences Services revenue grew 17.6% to $96.5M.
Profitability Reversal Achieved Net Income of $78.3M in 2025, a significant shift from Net Loss of ($114.8M) reported in 2024.
Strategic Divestiture Gain Completed CRYOPDP divestiture for $133.0M in Q2 2025, resulting in a $117.0M gain recognized in operations.
CGT Market Support Supported 760 clinical trials globally; 20 commercial therapies generated $33.4M revenue, increasing 28.6%.
關注風險
Component Supply Dependency Dependence on third-party component availability; delays or increased procurement costs could adversely affect financial performance.
Global Regulatory Exposure Operations face risks from changing international trade policies, currency fluctuations, and complex governmental regulations.
Product Liability Exposure Risk of liability claims exceeding insurance coverage, particularly concerning products used in human reproductive medicine.
Cybersecurity System Failure Critical information systems face constant cyberattacks; system compromise could materially harm operations and reputation.
未來展望
Digital Strategy Enhancement Established Enterprise Technology Group (ETG) to drive digital initiatives, integrating AI and advanced analytics across platforms.
Infrastructure Expansion Plans Opened Paris Global Supply Chain Center in 2025; planning another center in Santa Ana, California, late 2026.
MVE System Connectivity Plans to introduce MVE CryoVerse Ecosystem in 2026 for real-time monitoring and enhanced compliance visibility.
Future Capital Requirements Management recognizes potential need for additional equity or debt capital until sustained profitability is achieved.
同行對比
營業收入 (TTM)
$2.50B
$1.87B
$1.83B
毛利率 (最新季度)
89.1%
59.8%
48.4%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| SWBI | $614.01M | 51.1 | 3.3% | 20.2% |
| EBF | $542.07M | 12.9 | 14.1% | 2.9% |
| FWRD | $493.72M | -4.5 | -77.1% | 91.5% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
3.5%
溫和增長
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
25%
現金流需要關注
深度研究
下次財報:2026年4月30日
每股收益:-$0.22
|營業收入:$44.87M
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料